CRISPR gene editing leader Editas Medicine often makes biotech headlines for its therapies for sickle cell and retinal diseases. Less often does it make the news for its preclinical cancer pipeline – which could be why the company is reportedly considering a sale of these assets.

For Med Ad News’ 36th annual special report, the publication’s editors rank the world’s top 50 companies that generate revenue from prescription medicines and healthcare products.